REVTX-300 is under clinical development by Revelation Biosciences and currently in Phase I for Chronic Kidney Disease (Chronic Renal Failure). According to GlobalData, Phase I drugs for Chronic Kidney Disease (Chronic Renal Failure) have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how REVTX-300’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
REVTX-300 overview
REVTX-300 is under development for the treatment of acute kidney injury and chronic organ disease including chronic kidney disease and non-alcoholic steatohepatitis(NASH). The drug candidate is a phosphorylated hexaacyl disaccharide (PHAD) administered through intravenous route. It acts by targeting toll like receptor 4 (TLR4). It was under development for the treatment of myocarditis.
Revelation Biosciences overview
Revelation Biosciences is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. The company is headquartered in San Diego, California, the US.
For a complete picture of REVTX-300’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
